Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition marked by the accumulation of IgG4-positive plasma ...

Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm ...

Mumbai: Sanofi Consumer Healthcare India Limited has announced the upcoming departure of two of its senior leaders.Maithilee ...

The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, an investigational, novel, advanced, oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor, for two ...

Sanofi (NASDAQ:SNY) announced today that its investigational drug, rilzabrutinib, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for two rare diseases: warm ...

Sanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to Rilzabrutinib, an investigational, novel, advanced, oral, reversible Bruton’s tyrosine ...

Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response rates and reduced disease flares.

The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune hemolytic anemia, according to a press release from the manufacturer. There are currently no ...